Nonmetastatic microsatellite instability colorectal cancers nevertheless entailed a high risk for recurrence in stage III, especially when not treated with adjuvant chemotherapy.
In the treatment of IBD, combinations of biologics or a biologic and tofacitinib appeared to be generally safe and effective, according to a new systematic review and meta-analysis.
To take advantage of the latest targeted therapies in gastroesophageal cancer, physicians needed to identify patients who will benefit, but biomarker testing in this population continued to lag.